Tirzepatide Once Weekly for the Treatment of Obesity - Jastreboff, Ania M.; Aronne, Louis J.; Ahmad, Nadia N.; Wharton, Sean; Connery, Lisa; Alves, Breno; Kiyosue, Arihiro; Zhang, Shuyu; Liu, Bing; Bunck, Mathijs C.; Stefanski, Adam (The New England journal of medicine, 2022)
Keywords: Adult; Adverse events; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Antidiabetics; Body weight; Cardiovascular disease; Chronic illnesses; Clinical Medicine; Clinical Medicine General; Clinical trials; Diabetes; Diabetes mellitus; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Endocrinology; FDA approval; Gastric Inhibitory Polypeptide - administration & dosage; Gastric Inhibitory Polypeptide - therapeutic use; Gastroenterology; GIP protein; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - agonists; Glucagon-Like Peptides - therapeutic use; Humans; Injections, Subcutaneous; Lifestyles; Morbidity; Nutrition; Obesity; Obesity - complications; Obesity - drug therapy; Overweight; Peptides; Placebos; Statistical analysis; Treatment Outcome; Weight control; Weight Loss - drug effects